Welcome to our dedicated page for Enanta Pharmaceuticals SEC filings (Ticker: ENTA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Enanta Pharmaceuticals, Inc. filings document a clinical-stage biotechnology issuer focused on small-molecule therapies for viral infections and immunological diseases. Its Form 8-K disclosures cover financial results, Regulation FD clinical-data materials, research and development updates, material agreements and capital-structure information for common stock traded under ENTA on the Nasdaq Global Select Market.
Proxy and annual meeting filings record governance matters including director elections, advisory executive compensation votes, auditor ratification and amendments to the 2019 Equity Incentive Plan. Other event disclosures also document patent litigation matters, including proceedings involving U.S. Patent No. 11,358,953 and Pfizer's COVID-19 antiviral Paxlovid.
Enanta Pharmaceuticals, Inc. reported results from its March 11, 2026 annual meeting. Stockholders approved an amendment to the 2019 Equity Incentive Plan, increasing the shares of common stock reserved for issuance by 1,600,000 shares.
Two Class I directors, Bruce L.A. Carter, Ph.D., and Jay R. Luly, Ph.D., were re-elected to serve until the 2029 annual meeting. Stockholders also approved, on an advisory basis, the compensation of named executive officers and ratified PricewaterhouseCoopers LLP as independent registered public accounting firm for the fiscal year ending September 30, 2026.
Enanta Pharmaceuticals’ Chief Legal Officer Matthew Paul Kowalsky reported equity compensation activity in company stock. On February 12, 2026, he acquired 1,318 shares of common stock from performance share units that vested based on 2024-2025 research and development milestones. He also acquired 4,175 shares from a relative total stockholder return unit award tied to Enanta’s stock performance versus the Nasdaq Biotech Index. To cover withholding taxes from these vestings, 1,902 shares were automatically disposed of at $14.25 per share, leaving him with 3,591 shares of Enanta common stock held directly after the transactions.
Enanta Pharmaceuticals’ Chief Business Officer Brendan Luu reported equity compensation activity. On February 12, 2026, he acquired 1,575 shares of common stock through performance share units tied to 2024–2025 research and development milestones, and 4,987 shares through a relative total stockholder return unit award, both at $0 per share.
On the same date, 3,257 shares were automatically forfeited at $14.25 per share to cover withholding taxes arising from settlement of these awards. After these transactions, Luu directly beneficially owned 41,634 shares of Enanta common stock.
Enanta Pharmaceuticals' Chief Product Strategy Officer, Tara Lynn Kieffer, reported equity compensation transactions in Enanta common stock. On February 12, 2026, she acquired 1,575 shares through performance share units that vested based on 2024-2025 research and development milestones, as determined by the Compensation Committee. She also acquired 4,987 shares from a relative total stockholder return unit award tied to Enanta’s stock performance versus the Nasdaq Biotech Index over matching 60-day periods two years apart. To cover withholding taxes from these awards, 3,257 shares were automatically forfeited at a price of $14.25 per share. Following these transactions, she directly held 33,925 shares of Enanta common stock.
Enanta Pharmaceuticals Chief Medical Officer Scott T. Rottinghaus reported equity award activity in company stock. On February 12, 2026, he acquired 1,650 shares of common stock at $0 per share from performance share units that vested based on research and development milestones for the 2024-2025 period.
On the same date, he acquired an additional 5,225 shares at $0 per share from a relative total stockholder return unit award tied to Enanta’s performance versus the Nasdaq Biotech Index. Also on February 12, 2026, 3,413 shares were disposed of at $14.25 per share to satisfy withholding taxes related to settlement of these awards. After these transactions, he directly owned 25,254 shares of Enanta common stock.
Enanta Pharmaceuticals’ Chief Scientific Officer Or Yat Sun reported equity compensation activity. On February 12, 2026, Sun acquired 1,650 shares of common stock from performance share units tied to 2024–2025 R&D milestones and 5,225 shares from a relative total stockholder return unit award, both at $0 per share. On the same date, 3,413 shares were automatically forfeited at $14.25 per share to cover withholding taxes from settlement of these awards. Following these transactions, Sun directly owned 374,854 common shares.
Enanta Pharmaceuticals President and CEO Jay R. Luly, who is also a director, reported equity award activity in Enanta common stock. On February 12, 2026, he acquired 4,800 shares through performance share units tied to 2024-2025 R&D milestones and 15,200 shares from a relative total stockholder return unit award, both at no cash price. On the same date, 6,155 shares were automatically withheld and forfeited at $14.25 per share to cover tax obligations from these vestings. After these transactions, he directly beneficially owned 871,871 shares of Enanta common stock.
Deep Track Capital and affiliates report a 6.78% stake in Enanta Pharmaceuticals Inc. The group, including Deep Track Biotechnology Master Fund and David Kroin, beneficially owns 1,956,867 shares of Enanta common stock, with shared voting and dispositive power over all reported shares.
The ownership percentage is based on 28,862,601 Enanta common shares outstanding as of November 4, 2025, as referenced from the company’s Form 10-K. The reporting persons certify the shares are not held for the purpose of changing or influencing control of Enanta.
Enanta Pharmaceuticals, Inc. has filed a shelf registration statement on Form S-3 to offer and sell up to $150,000,000 of securities. The shelf covers common stock, preferred stock, debt securities, warrants and units that may be issued over time using prospectus supplements.
Enanta is a biotechnology company focused on small-molecule drugs for virology, including RSV, SARS‑CoV‑2, HCV and HBV, and for immunology indications such as atopic dermatitis, urticarias, asthma, COPD, CRSwNP and prurigo nodularis. Net proceeds from any offerings are intended for general corporate purposes, including R&D, commercialization, manufacturing, possible acquisitions and potential repayment or repurchase of future indebtedness or capital stock.